One page, thousands of outlets. See who else covered it.
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that it is discontinuing the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer or mNSCLC, based on the recommendation of the Independent Data Monitor
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
SYDNEY: Asian shares edged higher on Monday, led by Chinese stocks ahead of key economic data, while investors kept a wary eye on oil prices after sizeable gains last week amid a stalemate in the Gulf conflict.
An den asiatischen Börsen bleiben vor dem Hintergrund des Irankriegs größere Bewegungen aus. Anleger in Japan wetten indes auf eine Zinserhöhung im September.
The USD/CAD pair edges lower to around 1.3860 during the early European session on Monday. The US Dollar (USD) extends the decline against the Canadian Dollar (CAD) as traders pare bets on the US…
BNY's Wee Khoon Chong note Sweden’s Riksbank appears comfortable with its current policy stance as inflation stays below target, leaving two hikes in the repo path mainly as a risk acknowledgment.